Beam Therapeutics - BEAM Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares.
View BEAM analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month target prices for Beam Therapeutics' stock. Their BEAM share price forecasts range from $60.00 to $130.00. On average, they anticipate the company's share price to reach $87.67 in the next year. This suggests a possible upside of 69.9% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $79.69 at the beginning of the year. Since then, BEAM stock has decreased by 35.2% and is now trading at $51.60.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our BEAM earnings forecast.

Beam Therapeutics Inc. (NASDAQ:BEAM) released its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.08) by $0.06. The firm earned $16.65 million during the quarter, compared to analysts' expectations of $9.44 million. Beam Therapeutics had a negative net margin of 304.21% and a negative trailing twelve-month return on equity of 27.45%. The company's revenue was up 277433.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.23) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BEAM stock can currently be purchased for approximately $51.60.

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $3.63 billion and generates $51.84 million in revenue each year. The company earns $-370,640,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

The company employs 341 workers across the globe.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.